Susan Aldridge
|
In the popular view of nanomedicine, miniature robots equipped with a set of tools will one day patrol the inside of the body,
cleaning up atheroslerotic plaque, zapping cancer cells, and generally performing repair and maintenance. This highly futuristic
scenario owes much to a vision presented by Eric Drexler, the pioneer of nanotechnology, in the 1980s. In reality, nanomedicine
is making a slow, but steady, impact on the pharmaceutical industry. In 2006, Nature Materials estimated that there were approximately
130 nanodrugs or delivery systems in development across the globe,1 which, although is not many compared with the number of small molecules and biologics in the pipeline, is enough to create
an intriguing new product category.
The nanoscale
Nanotechnology involves engineering functional systems at the molecular scale. While Drexler is credited with the major development
of the field, the concept can be traced back to the physicist Richard Feynman who, in 1959, said: "There is plenty of room
at the bottom" when referring to the possibilities in the nanoworld.2 The nanoscale is really the molecular scale, with small organic molecules lying at the lower limit of this range, viruses
towards the upper end, and protein molecules and other biologics somewhere in the middle. Nanotechnology is well established
today in the computing, energy and electronics sectors, but less so in pharma and biotech.
Nanomedicine is, put simply, the application of nanotechnology to medicine. In its first issue, the journal Nanomedicine adopted a more precise definition of nanomedicine as 'the use of materials, of which at least one of their dimensions that
affects their function is in the scale range 1–100 nm, for a specific diagnostic or therapeutic purpose.'3 Then there is bionanotechnology — a broad and sometimes vague term that refers to the biomedical or biological application
of nanotechnology. This can encompass the use of biomolecules themselves as nanodevices. Nanobiotechnology is another term
in common use, which although is hard to define precisely, is generally understood as the use of nanotechnology in biotech
applications.For the pharma and biotech industries, the advantages of nanomedicine lie mainly in its ability to make drugs with better
pharmacokinetics and bioavailability. "Materials can have very different properties at the nanoscale," explains Dr David Sarphie,
CEO of Bio Nano Consulting, a joint venture between Imperial College and University College (all UK) that advises on the development
and commercialization of new biomedical products in the nanotechnology area. For example, carbon nanotubes, which are an allotrope
of carbon made of long cylindrical tubes, are exceptionally strong compared with more conventional forms of carbon.
Nano innovation
The nanomedicine products already on the market fall into five categories: nanoparticles, nanocrystals, dendrimers, liposomes
and micelles. The Fraunhofer Institute for Manufacturing Technology and Material Research Applications (Germany) and Bio-Gate,
Nürnberg, a spinout of the University of Erlangen (Germany), have revived silver, a traditional antimicrobial, in the form
of nanoparticles. Their technology can be used to coat medical instruments and devices, wound dressings, lab coats and bandages
to protect patients against infection. With antibiotic resistance reaching epidemic proportions, new approaches to fighting
infection will be welcomed. In a related development, smelly feet can be overcome by wearing socks impregnated with silver
nanoparticles that kill the bacteria responsible for foot odour.
Elan (Ireland) has commercialized its NanoCrystal technology, which involves reducing the size of crystalline drug particles
into the nanoscale to increase the drug surface area and aid the dissolution of poorly water-soluble compounds, thereby improving
bioavailability. The first nanocrystal product is a new version of the immunosuppressant sirolimus. As it is a solid dose
formulation, it is more easily stored and administered than the previous oral solution that needed to be refrigerated. As
patients are usually on sirolimus for life, the advantages are clear. Elan has also offered to help other companies put their
products into nanocrystal form.
The author says...
|
Another emerging class of nanodrug is the dendrimer, a precisely defined synthetic complex molecule. A dendrimer is synthesized
around a core molecule with branching functional groups, to which other branching molecules can be added in layers to create
a molecule with many functional groups on its surface. The nature of these groups can be tightly controlled and the advantage
of a dendrimer is that it can activate many receptors simultaneously, whereas a small molecule will only interact with one
receptor. Starpharma (Australia) is developing dendrimers based on the amino acid lysine (with its two branching amino groups)
for a variety of applications including HIV, genital herpes, drug delivery and small interfering RNA delivery, and already
has a vaginal microbiocide dendrimer product on the market for HIV, bacterial vaginosis, HPV and contraception.
Liposomal and micellar formulations of drugs bring them into the nanoscale, and have been used in a number of controlled-release
systems including: Doxil (Alza, USA), a liposomal formulation of the anticancer drug doxorubicin; Medicelle (NanoCarrier,
Japan), a micelle-based technology for anticancer drugs; and Basulin (Flamel Technologies, France), a long-acting insulin.
Meanwhile, conjugation of drugs with polyethylene glycol (PEG) is another popular nanotech application that improves the half-life
of drugs, such erthyropoetin for anaemia, and interferon-alpha for hepatitis C, meaning that the patient has to take fewer
doses, which can improve the quality of life for the patient in terms of fewer injections.
Quality Contract Manufacuturing for semi-solids and liquids
Achieve optimum FTIR performance, sensitivity, reliability and value with Shimadzu spectrometers.
Introducing the ACQUITY UPLC H-Class System, the new UPLC system for HPLC users
Celebrating 35 years of processing solutions! Join us, May 4-6, in Rosemont, IL.
Introducing the ACQUITY UPLC H-Class System, the new UPLC system for HPLC users
See the latest news from Optima Group pharma.
Buy new and used pharmaceutical equipment, used process equipment and laboratory equipment at LabX. Auctions, classifieds, and post FREE wanted ads to locate equipment.
Try a complimentary sample of the new ultra-pure gasket from Gore PharmBIO Products
Major Biotech & Pharmaceutical Equipment Auction from Pfizer, Merck & More
Special offers on new and improved products from Restek.